Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -27,156 | -89,270 | -62,468 | -44,490 | -19,888 |
| Depreciation Amortization | 551 | 2,657 | 2,097 | 1,485 | 800 |
| Accounts receivable | N/A | 30 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 1,135 | 953 | 200 | 279 | 552 |
| Other Working Capital | 2,115 | 2,761 | 169 | 172 | 305 |
| Other Operating Activity | 2,163 | 23,042 | 13,643 | 10,544 | 2,551 |
| Operating Cash Flow | $-21,192 | $-59,827 | $-46,359 | $-32,010 | $-15,680 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -296 | -1,668 | -1,152 | -994 | -690 |
| Purchase Of Investment | -36,028 | -280,681 | -159,754 | -159,755 | -159,754 |
| Sale Of Investment | 7,750 | 208,650 | 140,050 | 47,050 | 16,050 |
| Other Investing Activity | 0 | -1,800 | -1,800 | -1,800 | 0 |
| Investing Cash Flow | $-28,574 | $-75,499 | $-22,656 | $-115,499 | $-144,394 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -944 | -3,541 | -2,622 | -1,725 | -851 |
| Common Stock Issued | 26,427 | 1,649 | 1,250 | 938 | 509 |
| Other Financing Activity | -482 | -750 | -602 | -523 | -261 |
| Financing Cash Flow | $25,001 | $-2,642 | $-1,974 | $-1,310 | $-603 |
| Beginning Cash Position | 64,082 | 202,050 | 202,050 | 202,050 | 202,050 |
| End Cash Position | 39,317 | 64,082 | 131,061 | 53,231 | 41,373 |
| Net Cash Flow | $-24,765 | $-137,968 | $-70,989 | $-148,819 | $-160,677 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,192 | -59,827 | -46,359 | -32,010 | -15,680 |
| Capital Expenditure | -296 | -1,670 | -1,152 | -994 | -690 |
| Free Cash Flow | -21,488 | -61,497 | -47,511 | -33,004 | -16,370 |